Desmoid Tumor - 23 Studies Found

Withdrawn : Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors
:
  • Desmoid Tumors
  • Fibromatosis

: 2009-09-15
: Drug: Hydroxyurea Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients w
Completed : Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
: Desmoid Tumor
: 2006-02-06
: Drug: imatinib mesylate
Completed : National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES)
: Aggressive Fibromatosis
: 2016-07-15
:
  • Procedure: biopsy pre-therapeu
Completed : Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets
: Desmoid Type-fibromatosis
: 2015-01-28
: Drug: Toremifene Patients will receive 60 mg daily and then 180 daily in case of progression
Completed : Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients
: Desmoid-type Fibromatosis
: 2015-01-28
: Other: Observational approach Patients will be placed under wait and see approach without any specific t
Active, not recruiting : Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
: Desmoid-Type Fibromatosis
: 2014-02-17
:
  • Other: Laboratory Biomarker Analysis

Completed : Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors
:
  • The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an
  • Adjuvant Ther
    : 2013-06-26
    : Drug: 5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.
Available : Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies
:
  • Neoplasm
  • Desmoid Tumor

: 2016-11-02
: Drug: PF-03084014 Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084
Active, not recruiting : A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)
: Fibromatosis
: 2015-07-08
: Drug: Imatinib Imatinib 400 mg/day until disease progression
Completed : Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
:
  • Hormone Receptor-Positive Breast
  • Gynecologic